Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of candesartan cilexetil + amlodipine tablets in patients with mild to moderate essential hypertension uncontrolled after 4 weeks of monotherapy
CTR20242546Phase 3Completed
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Jul 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of candesartan cilexetil, amlodipine in essential hypertension, sponsored by Jiangxi Shimei Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
candesartan cilexetilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20242546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242546.